Tarlatumab (Clinical Trials and Research)
The development of Tarlatumab has been supported by several clinical trials. These studies have aimed to evaluate the safety, efficacy, and tolerability of the drug in patients with IPF.
- Reduction in lung function decline: Tarlatumab has shown the potential to slow down the progression of IPF, as measured by lung function tests.
- Improved quality of life: Patients treated with tarlatumab may experience
- improvements in their overall quality of life, including reduced symptoms like shortness of breath.
- Favorable safety profile: While further research is needed, tarlatumab has generally
- been well-tolerated by patients, with a manageable side effect profile.